



Mechanisms and Novel Therapeutic Approaches for Gliomas

Guest Editor:

Dr. Maria V.

Chatziathanasiadou

Department of Brain Sciences,
Faculty of Medicine, Imperial
College London, London W12
0NN, UK

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Gliomas, the most common type of primary malignant brain tumour, present significant clinical challenges. This is mainly due to their invasive nature, intratumour heterogeneity, immunosuppressive microenvironment, and the presence of the blood–brain barrier. Little progress has been achieved in glioma treatment over the last few decades, while the main therapeutic options are surgery, radiotherapy, and chemotherapy. Thus, there is an imperative need to deepen our current understanding of glioma mechanisms and develop cutting-edge therapeutic strategies.

This Special Issue aims to cover molecular and cellular glioma mechanisms, including molecular markers, signaling, tumour landscape, cell crosstalk, and immunity, as well as novel therapeutic approaches, such as metabolic therapies, immunotherapies, newly designed and repurposed drugs, and combination treatments.

We also welcome review manuscripts that present recently discovered molecular markers, therapeutic targets, tumour landscape characteristics, or innovative therapies from preclinical studies and clinical trials.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)